Susanne Rohrer

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study

Francisco J. Blanco, R Möricke, Eva Dokoupilová et al. · Arthritis & Rheumatology · 2017 · 182 citations

Medicine, Immunology, Pharmacotherapy +17

Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study

Christoph Hatz, Bettina Bally, Susanne Rohrer et al. · Vaccine · 2015 · 94 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2

Helena Marzo‐Ortega, Joachim Sieper, Alan Kivitz et al. · RMD Open · 2017 · 76 citations · Full text

Medicine, Pharmacotherapy, Inflammation +14

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

Eva Dokoupilová, Jacob Aelion, Tsutomu Takeuchi et al. · Scandinavian Journal of Rheumatology · 2018 · 41 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 <scp>MEASURE</scp> 3 Study

Karel Pavelká, Alan Kivitz, Eva Dokoupilová et al. · ACR Open Rheumatology · 2020 · 41 citations · Full text

Medicine, Pharmacotherapy, Inflammation +11